Premium
Pharmacokinetics and Pharmacodynamics of Once‐Daily Controlled‐Release Oxybutynin and Immediate‐Release Oxybutynin
Author(s) -
Reiz Joseph L.,
Salem Paulette,
Darke Andrew C.
Publication year - 2007
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006297226
Subject(s) - oxybutynin , pharmacokinetics , pharmacodynamics , crossover study , medicine , anesthesia , pharmacology , urology , chemistry , overactive bladder , alternative medicine , pathology , placebo
Oxybutynin is used to treat patients with urinary urgency, frequency, and urge incontinence. In this 2‐way, multiple‐dose, crossover study, the pharmacokinetics and pharmacodynamics of once‐daily controlled‐release oxybutynin were compared with immediate‐release oxybutynin. Eighteen healthy male volunteers received one 15‐mg controlled‐release oxybutynin tablet once daily for 5 days or one 5‐mg immediate‐release oxybutynin tablet every 8 hours for 5 days. The washout period between treatments was ≤7 days. The mean steady‐state AUC for oxybutynin following controlled‐release oxybutynin treatment was higher (73.0 ng·h/mL) than following immediate‐release oxybutynin treatment (53.6 ng·h/mL) ( P = .0001). The mean C max was lower for controlled‐release oxybutynin (5.7 ng/mL) than for immediate‐release oxybutynin (7.5 ng/mL) ( P = .0051), with a smaller fluctuation in oxybutynin plasma concentration for controlled‐release oxybutynin (135.6%) than for immediate‐release oxybutynin (319.3%) ( P = .0001). Mean stimulated saliva output was greater for controlled‐release oxybutynin, and mean dry mouth severity was less than immediate‐release oxybutynin.